Similar Papers

Paper Title
Journal
Date
Author
Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001).
M Ueno ... S Morita
Journal of Clinical Oncology | VOL. 29
M Ueno, et. al.M Ueno ... S Morita
20 May 2011
Quality of life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study.
Y Ohashi ... N Boku
Journal of Clinical Oncology | VOL. 29
Y Ohashi, et. al.Y Ohashi ... N Boku
20 May 2011
Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer.
Oki Nakano ... Shuji Terai
Cancer Medicine | VOL. 10
Oki Nakano, et. al.Oki Nakano ... Shuji Terai
16 May 2021
Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan.
Akira Fukutomi ... Kenji Yamao
Journal of Clinical Oncology | VOL. 30
Akira Fukutomi, et. al.Akira Fukutomi ... Kenji Yamao
20 May 2012
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
276MO Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
C-T Wu ... L-N Chien
Annals of Oncology | VOL. 35
C-T Wu, et. al.C-T Wu ... L-N Chien
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.